RWA Wealth Partners LLC Purchases 9,054 Shares of Becton, Dickinson and Company (NYSE:BDX)

RWA Wealth Partners LLC grew its position in shares of Becton, Dickinson and Company (NYSE:BDX) by 123.6% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 16,381 shares of the medical instruments supplier’s stock after purchasing an additional 9,054 shares during the quarter. RWA Wealth Partners LLC’s holdings in Becton, Dickinson and Company were worth $3,994,000 as of its most recent SEC filing.

Several other hedge funds have also recently added to or reduced their stakes in BDX. OFI Invest Asset Management bought a new stake in shares of Becton, Dickinson and Company in the 3rd quarter valued at $25,000. Fortitude Family Office LLC acquired a new stake in Becton, Dickinson and Company in the 4th quarter valued at $35,000. Venturi Wealth Management LLC boosted its position in Becton, Dickinson and Company by 552.0% during the fourth quarter. Venturi Wealth Management LLC now owns 163 shares of the medical instruments supplier’s stock valued at $40,000 after buying an additional 138 shares during the period. Arlington Trust Co LLC purchased a new stake in Becton, Dickinson and Company during the fourth quarter valued at about $41,000. Finally, Headlands Technologies LLC purchased a new stake in Becton, Dickinson and Company during the third quarter valued at about $55,000. Institutional investors own 86.97% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts recently issued reports on the stock. Barclays increased their price target on shares of Becton, Dickinson and Company from $301.00 to $305.00 and gave the stock an “overweight” rating in a research note on Monday, February 5th. Raymond James increased their price target on shares of Becton, Dickinson and Company from $269.00 to $275.00 and gave the stock an “outperform” rating in a research note on Wednesday, January 3rd. Two research analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $280.00.

Becton, Dickinson and Company Trading Down 0.1 %

Shares of BDX stock opened at $233.88 on Tuesday. Becton, Dickinson and Company has a 12-month low of $229.40 and a 12-month high of $287.32. The company has a current ratio of 1.08, a quick ratio of 0.64 and a debt-to-equity ratio of 0.56. The firm’s 50 day moving average is $239.81 and its 200 day moving average is $241.99. The stock has a market capitalization of $67.57 billion, a P/E ratio of 55.42, a P/E/G ratio of 1.93 and a beta of 0.43.

Becton, Dickinson and Company (NYSE:BDX) last issued its earnings results on Thursday, February 1st. The medical instruments supplier reported $2.68 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.39 by $0.29. Becton, Dickinson and Company had a net margin of 6.44% and a return on equity of 13.57%. The company had revenue of $4.71 billion for the quarter, compared to analysts’ expectations of $4.73 billion. During the same quarter last year, the company posted $2.98 earnings per share. The firm’s quarterly revenue was up 2.6% on a year-over-year basis. Research analysts expect that Becton, Dickinson and Company will post 12.94 earnings per share for the current year.

Insider Transactions at Becton, Dickinson and Company

In other news, SVP Thomas J. Spoerel sold 282 shares of Becton, Dickinson and Company stock in a transaction on Thursday, March 14th. The shares were sold at an average price of $238.29, for a total transaction of $67,197.78. Following the transaction, the senior vice president now owns 2,276 shares in the company, valued at approximately $542,348.04. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Corporate insiders own 0.31% of the company’s stock.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.